AbbVie and Gubra Sign $350M Deal for Obesity Drug Development

• AbbVie has entered a licensing agreement with Gubra to develop GUB014295, a long-acting amylin analog for obesity treatment.

• The deal includes a $350 million upfront payment, with potential milestone payments of up to $1.875 billion and tiered royalties on global sales.

AbbVie has announced a licensing agreement with Gubra to develop and commercialize GUB014295, a potential best-in-class, long-acting amylin analog for obesity treatment. The agreement marks AbbVie’s entry into the obesity market, an area of growing pharmaceutical focus.

GUB014295, currently in a Phase 1 clinical trial, is designed to activate amylin and calcitonin receptors. Amylin, a satiety hormone, plays a role in appetite suppression and delaying gastric emptying, making it a promising target for obesity treatment.

“As obesity continues to be a major global health challenge, our partnership with Gubra offers an opportunity to develop innovative treatments while driving long-term company growth,” said Robert A. Michael, chief executive officer of AbbVie.

Under the terms of the agreement, AbbVie will lead the global development and commercialization of GUB014295. Gubra will receive a $350 million upfront payment and may earn up to $1.875 billion in milestone payments, along with tiered royalties on net sales. The transaction is subject to regulatory approvals and customary closing conditions.

Henrik Blou, chief executive officer of Gubra, highlighted the potential of the collaboration, stating, “This partnership will accelerate the development of GUB014295 and build on the promising data from its Phase 1 single ascending dose trial.”